Literature DB >> 32378520

Comparison of antimicrobial susceptibilities of bacterial isolates between cured and uncured cases of bovine mastitis.

Kanako Ishihara1, Chihiro Sunagawa1, Takashi Haneishi2,3, Naoko Miyaguchi1, Natsumi Endo3, Tomomi Tanaka3.   

Abstract

To evaluate the effect of antimicrobial susceptibility on outcomes, we compared the minimum inhibitory concentrations (MICs) for Staphylococcus, Streptococcus, and the family Enterobacteriaceae from cured and uncured mastitis cases; milk shipment for uncured cases could not be resumed within 3 weeks after initial clinical examination. A higher MIC50 of ampicillin and a higher MIC90 of cefazolin for Enterobacteriaceae isolates were observed for cured rather than uncured cases with differences in ≥2 tubes. Endotoxins are generally released from Enterobacteriaceae upon antimicrobial treatment; their amounts are presumed to be greater in mastitis cases resulting from β-lactam antibiotic-susceptible rather than -resistant microbes. For staphylococcal and streptococcal isolates, the MIC50 and MIC90 of β-lactam antibiotics were similar for cured and uncured cases.

Entities:  

Keywords:  antimicrobial resistance; mastitis

Mesh:

Substances:

Year:  2020        PMID: 32378520      PMCID: PMC7399304          DOI: 10.1292/jvms.19-0692

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


Mastitis is considered one of the most highly incident diseases, causing high treatment costs and reduced milk shipment in the dairy industry [7]. Antimicrobial agents have been primarily administered to treat mastitis [15]. However, antimicrobial resistance is an increasing global health threat, potentially affecting the effective treatment of bacterial infections [19]. Therefore, clinical veterinarians should prudently use antimicrobials and should select antimicrobials expected to display a response on the basis of bacteriological analysis and the clinical conditions of diseased animals. However, clinical treatments for mastitis are often ineffective and cure rates are poor [6, 17]. It is important to identify mastitis cases in which antimicrobial treatment is ineffective before antimicrobial administration to reduce antimicrobial agent use. To evaluate the effect of antimicrobial resistance on resumption of milk shipment, we determined the minimum inhibitory concentrations (MICs) for causative bacterial isolates from mastitis cases and compared the MICs of isolates that were obtained from cured cases with those obtained from uncured cases. All dairy cattle diagnosed with bacterial mastitis between November 2013 and December 2014 by clinical veterinarians at the Central Veterinary Clinical Center of Chiba Prefectural Federated Agricultural Mutual Aid Association (Chiba NOSAI) were enrolled in this study. However, three cases of combined infections, where two or more bacterial species were isolated from a quarter of milk, were excluded. Each gargety quarter was defined as a case. Thus, 209 cases of 172 heads were involved in the study. Individual identification numbers of each animal and antimicrobial treatment (type of antimicrobial and the route and duration of administration) were confirmed through medical records. We confirmed if each cattle farmer could resume milk shipment for human consumption from a recovered gargety quarter within 3 weeks after initial clinical examination. That is, was confirmed from each farmer determined whether the milk can could be shipped [17]. In general, after antimicrobial treatment, farmers ask the dairy manufacturer to test somatic cell count, residual antimicrobials, and the quality of milk samples from treated quarters. If normal values are confirmed, the raw milk is shipped. It was confirmed that the quality of milk was within the standard of the ministerial ordinance of Ministry of Health, Labor and Welfare (MHLW) (No. 52 of 1951) based on Food Sanitation Act (No. 233 of 1947). Maximum residue levels for each antimicrobial in milk are established in a notification of MHLW (No. 499 of 2005). No blood contamination is also confirmed. Ninety-three cases (44.5%), wherein milk shipment was resumed within 3 weeks were defined as cured cases. Milk shipment was not resumed for 87 cases (41.6%), which were thus defined as uncured cases. Outcomes of resuming milk shipment were not confirmed for the remaining 29 cases (13.9%). Seventy-four cases (35.4%) were treated exclusively via intramammary infusion; 95 cases (45.5%) were treated via intramuscular injection and an intramammary infusion; and 21 cases (10.0%) were treated via intramuscular injection. Twelve cases (5.7%) were not treated with antimicrobials. We could not confirm the history of antimicrobial treatment for seven cases (3.3%). Intramammary infusions were administered to 169 cases (80.9%; 53 Streptococcus cases, 54 Staphylococcus cases, 38 Enterobacteriaceae cases, and 24 other cases), of which 154 (91.1%; 51 Streptococcus cases, 52 Staphylococcus cases, 30 Enterobacteriaceae cases, and 21 other cases) were administered cephalosporin antibiotics (primarily cefazolin). Other cases were treated with a combination of penicillin and aminoglycoside antibiotics (17 cases), kanamycin (8 Enterobacteriaceae cases) or erythromycin [one Trueperella pyogenes case (formerly Arcanobacterium pyogenes) [20]). Ten cases (5.9%) were treated with two or three types of intramammary infusions. Of the 209 cases, 116 (55.5%; 33 Streptococcus cases, 32 Staphylococcus cases, 33 Enterobacteriaceae cases, and 18 other cases) were treated via intramuscular injection of antimicrobials. Most cases (102 cases, 87.9%; 28 Streptococcus cases, 28 Staphylococcus cases, 30 Enterobacteriaceae cases, and 16 other cases) were intramuscularly administered ampicillin. Other cases were intramuscularly administered cefazolin (26 cases, 22.4%; two Streptococcus cases, six Staphylococcus cases, 14 Enterobacteriaceae cases, and 4 other cases), penicillin (8 cases), tetracycline (6 cases), enrofloxacin (6 cases), or tylosin (one case). Individual antimicrobials were administered to 90 cases. Two or more antimicrobials were intramuscularly administered to 26 cases. For bacteriological examination, quarter milk samples were kept cool and transported to the Central Veterinary Clinical Center of Chiba NOSAI. The samples were tested on the day of collection. Bacterial isolates obtained from these samples were transported to the Laboratory of Veterinary Public Health, Tokyo University of Agriculture and Technology. Upon initial analysis, the isolates were Gram-stained and hemolytic activity was confirmed on Muller-Hinton agar (Oxoid Ltd., Hampshire, UK) supplemented with 5% defibrinated sheep blood. Gram-negative bacilli were assessed for oxidase activity. These biochemical characteristics were confirmed using API 20E (bioMérieux, Japan Ltd., Tokyo, Japan). Catalase-negative cocci were identified through rapid ID 32 STREP api (bioMérieux, Japan Ltd.). Catalase-positive coccal isolates were identified based on the hsp60 sequence, as previously described [12]. Phylogenetic trees were constructed based on hsp60 sequences and are shown in Supplementary Fig. 1. Putative Staphylococcus aureus was identified using PCR [14]. Gram-positive bacterial isolates with clubbed ends arranged in a V formation grew gradually and were presumed to be T. pyogenes, identified using PCR (specific T. pyogenes) [8]. The isolates did not display the aforementioned characteristics and could not be identified using identification kits and PCR, but rather based on the 16S rDNA sequence [18]. Similarly, phylogenetic trees were constructed based on the 16S rDNA sequences and are shown in Supplementary Fig. 2. Bacterial species of isolates from the 209 cases are listed in Supplementary Table 1. The major causes of mastitis were Streptococcus spp. (70/209, 33.5%), Staphylococcus spp. (64/209, 30.6%), and Enterobacteriaceae (44/209, 21.1%). The minimal inhibitory concentration (MIC) was determined using the broth micro-dilution method with Dry Plate “Eiken” (Eiken Chemical Co., Ltd., Tokyo, Japan) for Staphylococcus spp. and Streptococcus spp. or Frozen Plate “Eiken” (Eiken Chemical Co., Ltd.) for the Enterobacteriaceae. The MIC50 and MIC90 were compared between isolates from cured and uncured cases for Staphylococcus spp., Streptococcus spp., and the Enterobacteriaceae (Table 1). Cases not yielding outcomes were excluded from this analysis.
Table 1.

Comparison of minimum inhibitory concentration (µg/ml) for causative bacteria by outcome (cured and uncured cases)

AntimicrobialsCured1)UncuredDifference
(a)(b)[log2 (b/a)]
Ampicillin
Staphylococcus spp. (a, n=36; b, n=23)
MIC500.250.51
MIC90220
Streptocuccus spp. (a, n=30; b, n=25)
MIC500.120.120
MIC900.50.50
Enterobacteriaceae (a, n=17; b, n=24)2)
MIC501288–4
MIC90>128>128NA
Esherichia coli (a, n=14; b, n=20)
MIC501284–5
MIC90>128>128NA

Cefazolin
Staphylococcus spp. (a, n=36; b, n=23)
MIC500.50.50
MIC90110
Streptocuccus spp. (a, n=30; b, n=25)
MIC500.250.51
MIC900.511
Enterobacteriaceae (a, n=17; b, n=24)2)
MIC5021–1
MIC90>644–5
Esherichia coli (a, n=14; b, n=20)
MIC5021–1
MIC90>64>64NA

1) Cases wherein milk shipment was resumed within 3 weeks were defined as cured cases. 2) The data of Enterobacteriaceae (n=41) includes the data of Escherichia coli (n=34). NA, no application; MIC, minimum inhibitory concentration. Underlined, MIC of isolates from cured cases was higher than those from uncured cases with a difference of ≥2 tubes.

1) Cases wherein milk shipment was resumed within 3 weeks were defined as cured cases. 2) The data of Enterobacteriaceae (n=41) includes the data of Escherichia coli (n=34). NA, no application; MIC, minimum inhibitory concentration. Underlined, MIC of isolates from cured cases was higher than those from uncured cases with a difference of ≥2 tubes. For 87 cases (48.3%), milk shipment could not be resumed within 3 weeks after the initial clinical examination. Of the 209 cases, 174 (83.3%) were treated with antimicrobial agents through intramammary infusion and/or intramuscular injection. Therefore, it was presumed that antimicrobial-resistant bacteria caused mastitis in several cases and did not respond to antimicrobial treatment. However, the MIC50 and MIC90 of ampicillin and cefazolin were the same or displayed a 1-tube difference between cured and uncured cases among Staphylococcus spp. and Streptococcus spp. (Table 1). Demon et al. reported that in vitro MIC data on cephalosporin did not fully concur with in vivo clinical outcomes in a mouse model of mastitis and changing the excipient for intramammary application improved the antimicrobial efficacy [5]. The accessibility of antimicrobials to infection sites is expected to adequately influence the therapeutic effect. The administered antimicrobials might not have reached the site of infection in uncured cases. Antibacterial agents are classified according to their potential distribution through the udder after intramammary administration [6]. Although cefazolin that was administered to most mastitis cases herein via intramammary infusion is not included in this classification, four kinds of cephalosporin are classified into ‘limited distribution’. Ampicillin that was administered to most cases via intramuscular injection is also classified into ‘limited distribution’ after parental administration. The effect of other factors on the outcome, e.g., dosage and administration of antimicrobials and the general status of cattle, should be evaluated. The higher MIC50 of ampicillin and the higher MIC90 of cefazolin for the Enterobacteriaceae isolates were observed from cured cases rather than uncured cases with a difference of ≥2 tubes (Table 1). Moreover, the MIC50 of ampicillin for Escherichia coli isolates from cured cases (128 µg/ml) was higher than that from uncured cases (4 µg/ml), displaying a difference of 5 tubes (Table 1). These results indicate that more cases of infections with β-lactam antibiotic-resistant isolates rather than -susceptible isolates could recover after treatment with antimicrobials, primarily β-lactam antibiotics including ampicillin and cefazolin. Endotoxins are the primary virulence factors in coliform bacteria. Clinical signs in acute coliform mastitis are induced by endotoxins and the subsequent release of inflammatory mediators [9, 16]. Antimicrobials reportedly induce endotoxin release [10]. Some β-lactam antibiotics inhibit penicillin-binding protein (PBP)-3, leading to filament formation. These filaments are associated with high endotoxin release [2]. In general, β-lactam antibiotic-resistant Enterobacteriaceae isolates produce β-lactamases [1, 11]. Filament-inducing concentrations of ceftazidime and cefotaxime for extended-spectrum β-lactamase (ESBL)-positive isolates were higher than those for ESBL-negative isolates [3]. Therefore, the amount of endotoxin released upon antimicrobial treatment was presumed to be higher in cases resulting from β-lactam antibiotic-susceptible isolates rather than -resistant isolates at the same concentration of β-lactam antibiotics. Increased endotoxin release might result in intractable mastitis in cases resulting from β-lactam antibiotic-susceptible isolates. Further study needs to determine concentrations of endotoxin for cases resulting from β-lactam antibiotic-susceptible and -resistant Enterobacteriaceae isolates. The breakpoints reported by the CLSI guidelines [4] and breakpoint for colistin reported by the European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org/clinical_breakpoints/) were applied, and antimicrobial resistance patterns were confirmed, and are summarized in Table 2 (64 Staphylococcus isolates), Table 3 (70 Streptococcus isolates), and Table 4 (44 Enterobacteriaceae isolates). Thirty-five of 64 Staphylococcus isolates (54.7%) were susceptible to all antimicrobials tested herein (Table 2). Almost all of the 10 antimicrobial resistance patterns displayed resistance to β-lactam antibiotics. To enhance the effect of treatment for staphylococcal mastitis, antimicrobials of other classes including macrolides and tetracycline may be selected based on antimicrobial susceptibilities according to the CLSI breakpoints.
Table 2.

Antimicrobial resistance patterns for Staphylococcus spp. isolated from mastitis samples

Antimicrobial resistance patternSubtotalS. aureus
PC-ABPC-CPDX-EM1
PC-ABPC-CEZ11
PC-ABPC-CPDX1
PC-ABPC-EM11
PC-ABPC-OFLX11
CPDX-EM1
PC-ABPC1915
PC-CPDX1
ABPC22
OFLX11
Susceptible3513

Total6434

PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (0.5 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (4 µg/ml); EM, erythromycin (8 µg/ml); OFLX, ofloxacin (4 µg/ml).

Table 3.

Antimicrobial resistance patterns for Streptococcus spp. isolated from mastitis samples

Antimicrobial resistance patternSubtotalS. dysgalactiaeS. uberis
PC-ABPC-KM-TC1
PC-KM-EM-TC11
KM-EM-TC22
PC-KM-TC44
PC-EM-TC33
EM-TC65
KM-OFLX1
KM-TC1072
PC-ABPC11
PC-KM32
PC-TC11
KM2113
PC211
TC422
Susceptible1081

Total702027

PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (8 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (8 µg/ml); EM, erythromycin (1 µg/ml); OFLX, ofloxacin (8 µg/ml).

Table 4.

Antimicrobial resistance patterns for family Enterobacteriaceae isolated from mastitis samples

Antimicrobial resistance patternSubtotalEsherichia coli
ABPC-CEZ-CPDX-ACV-CPDX/CVA-KM-TC-CP-ST11
ABPC-CEZ-CPDX-ACV-CPDX/CVA-KM-TC-ST11
ABPC-CEZ-CPDX-TC-CP-CL-NA-CPFX11
ABPC-CEZ-ACV-TC-CL1
ABPC-CEZ-CPDX-TC-CL11
ABPC-TC-NA-ST11
ABPC-KM-TC-ST11
ABPC-CEZ-ACV2
ABPC-TC-CL22
ABPC-TC-CP11
ABPC-TC-ST33
ABPC-TC33
TC-CL11
ABPC62
CL22
TC33
Susceptible1413

Total4436

ABPC, ampicillin (breakpoint, 32 µg/ml); CEZ, cefazolin (8 µg/ml); CPDX, cefpodoxime (8 µg/ml); ACV, amoxicillin/clavulanic acid (32/16 µg/ml); CPDX/CVA, cefpodoxime/clavulanic acid (32/4 µg/ml); KM, kanamycin (64 µg/ml); TC, tetracycline (16 µg/ml); CP, chloramphenicol (32 µg/ml); CL, colistin (4 µg/ml); NA, nalidixic acid (32 µg/ml); CPFX, ciprofloxacin (4 µg/ml).

PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (0.5 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (4 µg/ml); EM, erythromycin (8 µg/ml); OFLX, ofloxacin (4 µg/ml). PC, penicillin (breakpoint, 0.25 µg/ml); ABPC, ampicillin (8 µg/ml); CEZ, cefazolin (32 µg/ml); CPDX, cefpodoxime (8 µg/ml); EM, erythromycin (1 µg/ml); OFLX, ofloxacin (8 µg/ml). ABPC, ampicillin (breakpoint, 32 µg/ml); CEZ, cefazolin (8 µg/ml); CPDX, cefpodoxime (8 µg/ml); ACV, amoxicillin/clavulanic acid (32/16 µg/ml); CPDX/CVA, cefpodoxime/clavulanic acid (32/4 µg/ml); KM, kanamycin (64 µg/ml); TC, tetracycline (16 µg/ml); CP, chloramphenicol (32 µg/ml); CL, colistin (4 µg/ml); NA, nalidixic acid (32 µg/ml); CPFX, ciprofloxacin (4 µg/ml). Although only 10 Streptococcus isolates were susceptible to all tested antimicrobials (14.3%) (Table 3), the percentage of resistance to β-lactam antibiotics (22.9%) was low, concurrent with a previous report [13]. However, 25 of 55 cases (45.5%) were uncured. If clinical veterinarians select other classes of antimicrobials to treat mastitis caused by Streptococcus spp., they should focus on kanamycin and tetracycline resistance. Among the Enterobacteriaceae isolates, 16 antimicrobial resistance patterns were confirmed (Table 4). Of the 16 patterns, 13 patterns included ampicillin resistance. Considering that, endotoxins are released upon treatment with the aforementioned antimicrobials, antimicrobial treatment should not be recommended for cases of mastitis caused by Enterobacteriaceae. In conclusion, numerous mastitis cases caused by β-lactam antibiotic-resistant Enterobacteriaceae isolates could recover upon antimicrobial treatment rather than cases resulting from susceptible isolates, probably owing to low amounts of endotoxin released upon antimicrobial treatment for mastitis by β-lactam antibiotic-resistant isolates. The high endotoxin release induced by antimicrobial administration in cases resulting from susceptible isolates potentially inhibited resumption of milk shipment. Differences in MIC50 and MIC90 were not observed between Streptococcus spp. and Staphylococcus spp. isolated from cured cases and uncured cases. The low cure rate may not be attributed to mastitis caused by antimicrobial-resistant bacteria.
  18 in total

1.  Phylogenetic study of Staphylococcus and Macrococcus species based on partial hsp60 gene sequences.

Authors:  Anita Y C Kwok; Anthony W Chow
Journal:  Int J Syst Evol Microbiol       Date:  2003-01       Impact factor: 2.747

2.  Molecular identification and further characterization of Arcanobacterium pyogenes isolated from bovine mastitis and from various other origins.

Authors:  M Hijazin; H Ulbegi-Mohyla; J Alber; C Lämmler; A A Hassan; A Abdulmawjood; E Prenger-Berninghoff; R Weiss; M Zschöck
Journal:  J Dairy Sci       Date:  2011-04       Impact factor: 4.034

3.  16S ribosomal DNA amplification for phylogenetic study.

Authors:  W G Weisburg; S M Barns; D A Pelletier; D J Lane
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

4.  Proteolytic and proteomic changes in milk at quarter level following infusion with Escherichia coli lipopolysaccharide.

Authors:  K Hinz; L B Larsen; O Wellnitz; R M Bruckmaier; A L Kelly
Journal:  J Dairy Sci       Date:  2012-04       Impact factor: 4.034

Review 5.  Bovine mastitis and intramammary drug delivery: review and perspectives.

Authors:  P Gruet; P Maincent; X Berthelot; V Kaltsatos
Journal:  Adv Drug Deliv Rev       Date:  2001-09-01       Impact factor: 15.470

6.  Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis.

Authors:  L Suojala; H Simojoki; K Mustonen; L Kaartinen; S Pyörälä
Journal:  J Dairy Sci       Date:  2010-05       Impact factor: 4.034

7.  The intramammary efficacy of first generation cephalosporins against Staphylococcus aureus mastitis in mice.

Authors:  Dieter Demon; Carolin Ludwig; Koen Breyne; David Guédé; Julia-Charlotte Dörner; Robrecht Froyman; Evelyne Meyer
Journal:  Vet Microbiol       Date:  2012-05-22       Impact factor: 3.293

Review 8.  Economic effects of bovine mastitis and mastitis management: a review.

Authors:  T Halasa; K Huijps; O Østerås; H Hogeveen
Journal:  Vet Q       Date:  2007-03       Impact factor: 3.320

9.  Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.

Authors:  Jacqueline Buijs; Anthonius S M Dofferhoff; Johan W Mouton; Jos W M van der Meer
Journal:  J Antimicrob Chemother       Date:  2007-03-29       Impact factor: 5.790

10.  Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.

Authors:  J Buijs; A S M Dofferhoff; J W Mouton; J H T Wagenvoort; J W M van der Meer
Journal:  Clin Microbiol Infect       Date:  2008-02-05       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.